Sign up Australia
Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers promotes glaucoma surgery device in China

Ellex Medical Lasers (ASX:ELX) has commenced clinical training of physicians in China in the use of the Ellex iTrack™ minimally invasive glaucoma surgery (MIGS) device.
Ellex Medical Lasers promotes glaucoma surgery device in China
Ellex Medical Lasers promotes glaucoma surgery device in China

iTrack is an illuminated, micron-scale microcatheter, which enables physicians to perform canaloplasty for glaucoma patients.

This is the first program of clinical training in China for physicians in the ab interno canaloplasty (ABiC) technique using iTrack.

To date, sales in China have been limited because only the more complex ABiC surgery technique has been marketed.

Ellex’s program in China to relaunch iTrack for the simpler, faster ABiC technique is expected to be well received.

The training programs will be conducted at leading hospitals and teaching institutions in Shanghai and Beijing during 12-17 December 2016.

It is worth noting that Ellex iTrack™ is the only MIGS device in the world currently approved by the Chinese medical device regulatory authority for sale in China.

The current spend in China for the treatment of eye diseases is expected to double over the next five years, growing at a CAGR of 15% to reach US$5.3 billion per annum by 2021.

This growing demand, combined with strong global interest in MIGS, offers a favourable market outlook for Ellex iTrack.

Earlier this month, Ellex raised $10.3 million from a placement of shares with Australian and New Zealand investors, at $1.46 per share.

The funds will be used to accelerate the development of the company’s MIGS business focussed on the U.S. and Chinese markets.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

Newswire
November 30 2016

Related Articles

Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
Frosties Box
December 05 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use